Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic bone marrow-derived mesenchymal stem cells (UTHealth Houston, 912b25)
- Development stage
- Unknown
- Lead developer
- University of Texas Health Science Center at Houston
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic bone marrow-derived mesenchymal stem cells (allo-hMSCs) are an investigational cell therapy being developed by Dr. Mya Schiess and colleagues at UTHealth Houston for the treatment of Parkinson's disease. The therapy consists of mesenchymal stem cells harvested from the bone marrow of healthy donors, which are then expanded and administered to patients via intravenous infusion. The primary mechanism of action involves immunomodulation to address neuroinflammation, a critical factor in the pathogenesis and progression of Parkinson's disease. By secreting various anti-inflammatory factors and interacting with the host's immune cells, the allo-hMSCs aim to restore homeostasis to the neuronal-glial microenvironment and potentially slow neurodegeneration. The program has completed Phase 1 safety testing and has moved into Phase 2 randomized, double-blind, placebo-controlled trials.
- Other names
- allogeneic human mesenchymal stem cellsallo-hMSCs
Beyond the preview
Go deeper on allogeneic bone marrow-derived mesenchymal stem cells (UTHealth Houston, 912b25).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic bone marrow-derived mesenchymal stem cells (UTHealth Houston, 912b25).